Pruritus Pipeline Overview 2024: FDA Approvals and Key Developments by DelveInsight | Pfizer, Sanofi, Actavis, AbbVie, Astellas Pharma, Cara Therapeutics, EPI Health LLC, Galderma Laboratories LP

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pruritus pipeline constitutes 20+ key companies continuously working towards developing 25+ Pruritus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Pruritus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Pruritus Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pruritus Market.

Some of the key takeaways from the Pruritus Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Pruritus treatment therapies with a considerable amount of success over the years.

*
Pruritus companies working in the treatment market are Kamari Pharma Ltd, Mirum Pharmaceuticals, Haisco Pharmaceuticals, AB Science, Vanda Pharmaceuticals, Akron Children's Hospital, Xizang Haisco Pharmaceutical, GlaxoSmithKline, Escient Pharmaceuticals, Vifor Fresenius Medical Care, Qilu Pharmaceutical (Hainan), Cara Therapeutics, Inc., Keymed Biosciences Co.Ltd, Clexio Biosciences Ltd., Mirum Pharmaceuticals, Inc., DermBiont, Inc., Incyte Corporation, and others, are developing therapies for the Pruritus treatment

*
Emerging Pruritus therapies in the different phases of clinical trials are- KM-001, Volixibat, HSK21542, Masitinib, Tradipitant, Dupilumab, HSK21542 tablet, Linerixibat, EP547, Difelikefalin Injection, QLG2198, difelikefalin, CM310, CLE-400, Volixibat, DBI-001 Gel, ruxolitinib cream, and others are expected to have a significant impact on the Pruritus market in the coming years.

*
In March 2024, Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC).

*
In June 2023, The U.S. Food and Drug Administration (FDA) approved Bylvay (odevixibat) for treating severe pruritus (itching) in patients aged 12 months and older with Alagille syndrome, a condition that impedes bile flow from the liver to the small intestine.

Pruritus Overview

Pruritus, commonly known as itching, is an uncomfortable sensation on the skin that provokes the urge to scratch. It can be a symptom of various conditions, ranging from minor irritations to serious underlying diseases.

Get a Free Sample PDF Report to know more about Pruritus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pruritus-pipeline-insight [https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Pruritus Drugs Under Different Phases of Clinical Development Include:

*
KM-001: Kamari Pharma Ltd

*
Volixibat: Mirum Pharmaceuticals

*
HSK21542: Haisco Pharmaceuticals

*
Masitinib: AB Science

*
Tradipitant: Vanda Pharmaceuticals

*
Dupilumab: Akron Children's Hospital

*
HSK21542 tablet: Xizang Haisco Pharmaceutical

*
Linerixibat: GlaxoSmithKline

*
EP547: Escient Pharmaceuticals

*
Difelikefalin Injection: Vifor Fresenius Medical Care

*
QLG2198: Qilu Pharmaceutical (Hainan)

*
difelikefalin: Cara Therapeutics, Inc.

*
CM310: Keymed Biosciences Co.Ltd

*
CLE-400: Clexio Biosciences Ltd.

*
Volixibat: Mirum Pharmaceuticals, Inc.

*
DBI-001 Gel: DermBiont, Inc.

*
ruxolitinib cream: Incyte Corporation

Pruritus Route of Administration

Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Intravenous

*
Subcutaneous

*
Parenteral

*
Topical

Pruritus Molecule Type

Pruritus Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Pruritus Pipeline Therapeutics Assessment

*
Pruritus Assessment by Product Type

*
Pruritus By Stage and Product Type

*
Pruritus Assessment by Route of Administration

*
Pruritus By Stage and Route of Administration

*
Pruritus Assessment by Molecule Type

*
Pruritus by Stage and Molecule Type

DelveInsight's Pruritus Report covers around 25+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Pruritus product details are provided in the report. Download the Pruritus pipeline report to learn more about the emerging Pruritus therapies [https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Pruritus Therapeutics Market include:

Key companies developing therapies for Pruritus are - Actavis, AbbVie Inc., Astellas Pharma Inc., Cara Therapeutics, EPI Health LLC, Galderma Laboratories LP, Ocera Therapeutics Inc., Pfizer Inc., Sanofi, Trevi Therapeutics, and others.

Pruritus Pipeline Analysis:

The Pruritus pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Pruritus with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pruritus Treatment.

*
Pruritus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Pruritus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pruritus market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pruritus drugs and therapies [https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Pruritus Pipeline Market Drivers

*
Increasing Prevalence of Skin Disorders, Technological Advancements, are some of the important factors that are fueling the Pruritus Market.

Pruritus Pipeline Market Barriers

*
However, High Development Costs, Generic Competition, and other factors are creating obstacles in the Pruritus Market growth.

Scope of Pruritus Pipeline Drug Insight

*
Coverage: Global

*
Key Pruritus Companies: Kamari Pharma Ltd, Mirum Pharmaceuticals, Haisco Pharmaceuticals, AB Science, Vanda Pharmaceuticals, Akron Children's Hospital, Xizang Haisco Pharmaceutical, GlaxoSmithKline, Escient Pharmaceuticals, Vifor Fresenius Medical Care, Qilu Pharmaceutical (Hainan), Cara Therapeutics, Inc., Keymed Biosciences Co.Ltd, Clexio Biosciences Ltd., Mirum Pharmaceuticals, Inc., DermBiont, Inc., Incyte Corporation, and others

*
Key Pruritus Therapies: KM-001, Volixibat, HSK21542, Masitinib, Tradipitant, Dupilumab, HSK21542 tablet, Linerixibat, EP547, Difelikefalin Injection, QLG2198, difelikefalin, CM310, CLE-400, Volixibat, DBI-001 Gel, ruxolitinib cream, and others

*
Pruritus Therapeutic Assessment: Pruritus current marketed and Pruritus emerging therapies

*
Pruritus Market Dynamics: Pruritus market drivers and Pruritus market barriers

Request for Sample PDF Report for Pruritus Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Pruritus Report Introduction

2. Pruritus Executive Summary

3. Pruritus Overview

4. Pruritus- Analytical Perspective In-depth Commercial Assessment

5. Pruritus Pipeline Therapeutics

6. Pruritus Late Stage Products (Phase II/III)

7. Pruritus Mid Stage Products (Phase II)

8. Pruritus Early Stage Products (Phase I)

9. Pruritus Preclinical Stage Products

10. Pruritus Therapeutics Assessment

11. Pruritus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pruritus Key Companies

14. Pruritus Key Products

15. Pruritus Unmet Needs

16 . Pruritus Market Drivers and Barriers

17. Pruritus Future Perspectives and Conclusion

18. Pruritus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pruritus-pipeline-overview-2024-fda-approvals-and-key-developments-by-delveinsight-pfizer-sanofi-actavis-abbvie-astellas-pharma-cara-therapeutics-epi-health-llc-galderma-laboratories-lp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.